CAT scan of brain, Alzheimer's disease (Credit: Getty Images)
Lilly’s Alzheimer’s drug donanemab slows cognitive decline by 35% in PhIII, setting up showdown with Eisai’s Leqembi
At long last, Eli Lilly has found success in its decades-long effort to develop a treatment for Alzheimer’s disease.
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
